Considering certain systemic effects of PDE5 inhibitors [88], and that even a relatively minor decrease in MAP can be deleterious in patients with advanced CLD, the combination of these agents with NSBB may be unsafe in advanced CLD. Here, PDE5A is linked to congenital secretory chloride diarrhea 1.